AstraZeneca Bets $2 Billion on Summit’s Dual-Target Cancer Drug
Summit and AstraZeneca will co-develop ivonescimab combinations, starting with GI cancers. Each company keeps rights to its own medicines.
/ 10 items
#SMMT↓
Ivonescimab Cuts Death Risk 27% vs Keytruda, With Strongest Gain in High PD-L1 Patients
HARMONi-2: Summit’s Ivonescimab extended median survival by 8.2 months vs Keytruda. 42% lower death risk in PD-L1-high patients.
Summit Therapeutics Upgraded to Buy by Jefferies on Late-2026 PFS Outlook
Analysts see a likely PFS win in HARMONi-3 later in 2026.
Summit’s Ivonescimab Delivers First Major PFS Win in EGFR-Mutated Lung Cancer After TKI Failure
HARMONi Phase 3 results in The Lancet Oncology show ivonescimab + chemo cuts progression risk nearly in half for post-TKI EGFR-mutated NSCLC.
Summit Therapeutics Warns of Cash Crunch That Could Threaten Operations Despite Strong Cancer Drug Progress
Summit Therapeutics says its cash won’t cover operations for a year, raising going-concern concerns. Shares fall as the company seeks funding while advancing ivonescimab development.
Bernstein Says Sell SMMT: Why Summit Therapeutics Stock Could Drop More
Bernstein remains bearish on Summit, citing doubts about trial success and expecting weak results ahead.